Published in Clin Pharmacol Ther on November 01, 1974
Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens. Nature (1980) 2.85
Effect of environmental factors on drug metabolism: decreased plasma half-life of antipyrine in workers exposed to chlorinated hydrocarbon insecticides. Clin Pharmacol Ther (1969) 2.75
Response of hepatic microbodies to a hypolipidemic agent, ethyl chlorophenoxyisobutyrate (CPIB). J Cell Biol (1966) 2.29
Report of the Institute of Medicine Committee on the Efficacy and Safety of Halcion. Arch Gen Psychiatry (1999) 2.03
Drugs as etiologic factors in the Stevens-Johnson syndrome. Am J Med (1968) 1.98
Plasma protein binding of tricyclic anti-depressants in man. Biochem Pharmacol (1969) 1.86
Pharmacokinetics of methotrexate. Clin Pharmacol Ther (1973) 1.55
The effect of spironolactone on antipyrine metabolism in man. Pharmacology (1973) 1.31
Computer-controlled infusion of intravenous dexmedetomidine hydrochloride in adult human volunteers. Anesthesiology (1993) 1.30
Correlation of the plasma elimination of antipyrine and the appearance of 4-hydroxy antipyrine in the urine of man. Biochem Pharmacol (1974) 1.28
Absorption of orally given digoxin preparations. JAMA (1972) 1.27
The effects of urine pH and plasma protein binding on the renal clearance of disopyramide. Clin Pharmacokinet (1977) 1.25
Effect of route of administration and effusions on methotrexate pharmacokinetics. Cancer Res (1974) 1.22
Nafenopin-induced hepatic microbody (peroxisome) proliferation and catalase synthesis in rats and mice. Absence of sex difference in response. J Cell Biol (1974) 1.21
Di-(2-ethylhexyl)phthalate: an industrial plasticizer induces hypolipidemia and enhances hepatic catalase and carnitine acetyltransferase activities in rat and mice. Life Sci (1976) 1.14
Phenytoin: pharmacokinetics and bioavailability. Clin Pharmacol Ther (1976) 1.14
Long-term effects of clofibrate (Atromid-S) on serum lipids in man. Circulation (1969) 1.11
Theophylline bioavailability following chronic dosing of an elixir and two solid dosage forms. J Pharm Sci (1978) 1.09
Mitogenic and carcinogenic effects of a hypolipidemic peroxisome proliferator, [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14, 643), in rat and mouse liver. Cancer Res (1979) 1.09
Drugs and drug metabolites as environmental contaminants: chlorophenoxyisobutyrate and salicyclic acid in sewage water effluent. Life Sci (1977) 1.07
Clinical complications of corticosteroid therapy. A selected review. Med Clin North Am (1973) 1.06
Metabolic responses to acute and chronic L-dopa administration in patients with parkinsonism. N Engl J Med (1972) 1.04
Effect of in vivo elevation of free fatty acids on protein binding of drugs. Pharmacology (1974) 1.02
Tumors in male rats fed ethyl chlorophenoxyisobutyrate, a hypolipidemic drug. Cancer Res (1979) 1.00
The alteration of plasma proteins in uremia as reflected in their ability to bind digitoxin and diphenylhydantoin. Pharmacology (1972) 1.00
Correlation between plasma diphenhydramine level and sedative and antihistamine effects. Clin Pharmacol Ther (1978) 0.99
Clinical pharmacokinetics of methotrexate. Clin Pharmacokinet (1978) 0.99
Prescription writing by generic name and drug cost. J Chronic Dis (1967) 0.96
Hepatic effects of some [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid (WY-14,643) analogs in the mouse. Arch Int Pharmacodyn Ther (1977) 0.95
A comparative study of drug metabolism in the isolated perfused liver and in vivo in rats. Eur J Pharmacol (1970) 0.95
Drug interactions with warfarin. Arch Intern Med (1968) 0.95
Effect of portacaval shunt on the disposition of drugs with and without first-pass effect. J Pharmacol Exp Ther (1975) 0.94
Microbodies in experimentally altered cells. VI. Thyroxine displacement from plasma proteins and clofibrate effect. Arch Int Pharmacodyn Ther (1969) 0.93
Drug interactions. Pharmacol Physicians (1970) 0.93
Drug protein binding and the nephrotic syndrome. Clin Pharmacokinet (1976) 0.92
Pharmacokinetics of drugs in patients with the nephrotic syndrome. J Clin Invest (1975) 0.92
Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine in humans. Cancer Res (1974) 0.92
Induction of salicyluric acid formation in rheumatoid arthritis patients treated with salicylates. Clin Pharmacokinet (1983) 0.87
The effect of butoxamine on catecholamine-induced metabolic changes in humans. Clin Pharmacol Ther (1966) 0.87
Absorption and excretion of clindamycin-2-phosphate in children after intramuscular injection. Clin Pharmacol Ther (1972) 0.86
Clofibrate effect on catecholamine-induced metabolic changes in humans. Metabolism (1968) 0.86
Association between clinical cardiac status, laboratory parameters, and digoxin usage. Am Heart J (1976) 0.85
Hepatic peroxisome proliferation: induction by BR-931, a hypolipidemic analog of WY-14,643. Arch Int Pharmacodyn Ther (1978) 0.85
Absorption of digoxin from different oral preparations in normal subjects during steady state. Clin Pharmacol Ther (1974) 0.85
Plasma levels and excretion of estrogens in urine in chronic lever disease. Gastroenterology (1975) 0.85
Theophylline bioavailability: a comparison of the oral absorption of a theophylline elixir and two combination theophylline tablets to intravenous aminophylline. Am Rev Respir Dis (1977) 0.84
Disposition kinetics of disopyramide in patients with renal insufficiency. Biopharm Drug Dispos (1981) 0.84
Diphenylhydantoin potency and plasma protein binding. J Pharmacol Exp Ther (1975) 0.83
Bioavailability of aminosalicylic acid and its various salts in humans. 3. Absorption from tablets. J Pharm Sci (1974) 0.83
Effects of selected hypolipidemic drugs on cell ultrastructure. Fed Proc (1971) 0.83
Metabolic disposition of antipyrine in patients with lung cancer. Cancer Res (1977) 0.82
1-methyl-4piperidyl-bis (P-chlorophenoxy) acetate: a new hypolipidemic peroxisome proliferator. Res Commun Chem Pathol Pharmacol (1975) 0.82
Pharmacology of hypolipidemic drugs. Introduction. Fed Proc (1971) 0.81
Diphenylhydantoin: correlation between protein binding and albumin concentration. Klin Wochenschr (1975) 0.81
Kinetics, salivary excretion of amphetamine isomers, and effect of urinary pH. Clin Pharmacol Ther (1978) 0.81
Topical application of lindane cream (Kwell) and antipyrine metabolism. J Invest Dermatol (1980) 0.81
Metabolic responses to plasma concentrations of theophylline. Clin Pharmacol Ther (1979) 0.81
Quantitation of lidocaine and its deethylated metabolites in plasma and urine by gas chromatography-mass fragmentography. J Chromatogr (1978) 0.81
Pharmacokinetic investigations in elderly patients. Clinical and ethical considerations. Clin Pharmacokinet (1990) 0.80
The interaction between halofenate and propranolol. Clin Pharmacol Ther (1976) 0.80
Comparison of charcoal and attapulgite as gastrointestinal sequestrants in acute drug ingestions. Clin Toxicol (1971) 0.80
A two-year crossover therapeutic trial with halofenate and clofibrate. Am J Med Sci (1977) 0.80
Gynecomastia induced in normal males by spironolactone. Clin Pharmacol Ther (1978) 0.79
The effect of DDD on barbiturate and steroid-induced hypnosis in the dog and rat. Biochem Pharmacol (1966) 0.79
Serum digitoxin in uremic patients. Clin Pharmacol Ther (1972) 0.79
Species differences in the plasma protein binding of desipramine. J Pharm Pharmacol (1968) 0.79
The alteration of plasma proteins in uremia as reflected in the ability to bind diphenylhydantoin. Ann N Y Acad Sci (1973) 0.78
Bioavailability of aminosalicylic acid and its various salts in humans IV: comparison of four brands of the sodium salt. J Pharm Sci (1974) 0.78
Hepatic catalase is not essential for the hypolipidemic action of peroxisome proliferators. Proc Soc Exp Biol Med (1977) 0.78
Placental transfer and fetal urinary excretion of gentamicin during constant rate maternal infusion. Pediatr Res (1975) 0.78
Inhibition of amphetamine tolerance and metabolism by propranolol. J Pharmacol Exp Ther (1974) 0.77
Clinical pharmacokinetics of disopyramide. J Pharmacokinet Biopharm (1982) 0.76
One-year trials with halofenate, clofibrate, and placebo. Clin Pharmacol Ther (1976) 0.76
Bioavailability studies on p-aminosalicylic acid and its various salts in man. II. Comparison of parasal and pascorbic. Am Rev Respir Dis (1973) 0.76
Pharmacokinetics of hydralazine and its acid-labile hydrazone metabolites in relation to acetylator phenotype. J Pharmacokinet Biopharm (1980) 0.75
Methapyrilene kinetics and dynamics. Clin Pharmacol Ther (1981) 0.75
Quantitation of N-demethylantipyrine in biological samples and isolation and characterization of its glucuronic acid conjugate. Drug Metab Dispos (1978) 0.75
Glucuronic acid conjugates of clofibrate: four isomeric structures. Life Sci (1981) 0.75
Hyperinsulinemia secondary to chronic administration of mazindol and d-amphetamine. Am J Med Sci (1971) 0.75
Effect of drugs which alter microsomal drug-metabolizing enzyme activity on rat hepatic cholesterol biosynthesis. Biochem Pharmacol (1977) 0.75
Clinical principles of drug interactions in the adult patient. Ann N Y Acad Sci (1976) 0.75
Identification of methotrexate and folic acid analogs by mass spectrometry. Biomed Mass Spectrom (1978) 0.75
Glutethimide and 4-OH glutethimide: pharmacokinetics and effect on performance in man. Clin Pharmacol Ther (1977) 0.75
Effect of oxygen tension on drug levels and pharmacological action in the intact animal. Proc Soc Exp Biol Med (1969) 0.75
Quantitation of chlordiazepoxide and its metabolites in biological fluids by thin-layer chromatography. J Chromatogr (1978) 0.75
Pamatolol: phase I evaluation of the pharmacodynamics of a cardioselective beta adrenoceptor blocking drug. Clin Pharmacol Ther (1978) 0.75
A comparative trial of clofibrate and nicotinyl alcohol tartrate in hyperlipoproteinemic patients. Am J Med Sci (1979) 0.75
Insecticides: effect on drug metabolism. Clin Pharmacol Ther (1977) 0.75
Application of metabolic data to the evaluation of drugs. JAMA (1970) 0.75
Kinetics of pamatolol, a cardioselective beta adrenoreceptor blocker. Clin Pharmacol Ther (1979) 0.75
Effective drug use. Drug utilization by the practicing physician. J Kans Med Soc (1972) 0.75
Separation and identification of impurities in parenteral methotrexate dosage forms. Cancer Treat Rep (1978) 0.75
Nitroglycerin patches: further comments. Am Pharm (1982) 0.75
Tumors potentiating catecholamine-induced hypertension. Life Sci I (1971) 0.75
The effect of concurrent oral administration of propranolol and disopyramide on cardiac function in healthy men. Circulation (1980) 0.75
Treatment of angina pectoris with chromonar hydrochloride. Clin Pharmacol Ther (1968) 0.75
Current status of drugs used to treat hyperlipoproteinemias. Drug Ther (1982) 0.75
Bioavailability of digoxin-hydroquinone complex: a new oral digoxin formulation. J Pharm Sci (1977) 0.75
Evidence that inhibition of hepatic drug oxidation by tumors is mediated by a circulating humor. Proc Soc Exp Biol Med (1972) 0.75
Clinical implications of drug metabolism--introduction. Chem Biol Interact (1971) 0.75